Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CCNC | P24863 | 7/20 | 0.44 |
| ▸ | CDK8 | P49336 | 7/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701730 | 0.91 | KMT2A (0.48) | MAPTKDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL6698658 | 0.88 | KMT2A (0.50) | MAPTKDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL6698133 | 0.86 | GAA (0.47) | MAPTKDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL6701834 | 0.86 | TSHR (0.47) | MAPTKDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL6701311 | 0.85 | KMT2A (0.45) | MAPTKDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL6701774 | 0.85 | KDM4E (0.47) | MAPTKDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL6702347 | 0.85 | OPRD1 (0.44) | MAPTKDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL6701825 | 0.85 | USP2 (0.50) | MAPTKDM4EALDH1A1KMT2AHPGD | |
| SCHEMBL6693686 | 0.84 | KMT2A (0.49) | MAPTALDH1A1KMT2AHPGDMAPK1 | |
| SCHEMBL6699164 | 0.84 | KMT2A (0.47) | MAPTKDM4EALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | PLA2G4C, PLA2G4B, PLA2G5 | MAPT 4701/4885KDM4E 3920/4885ALDH1A1 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.